

# Diana O Perkins

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2105749/diana-o-perkins-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162  
papers

16,837  
citations

45  
h-index

129  
g-index

166  
ext. papers

19,719  
ext. citations

5.7  
avg, IF

6.08  
L-index

#	Paper	IF	Citations
162	Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1209-23	59.2	4423
161	Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. <i>Schizophrenia Bulletin</i> , <b>2003</b> , 29, 703-15	1.3	1175
160	Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. <i>Archives of General Psychiatry</i> , <b>2008</b> , 65, 28-37		1004
159	Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. <i>American Journal of Psychiatry</i> , <b>2005</b> , 162, 1785-804	11.9	896
158	Practice guideline for the treatment of patients with schizophrenia, second edition. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 1-56	11.9	855
157	The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. <i>Schizophrenia Bulletin</i> , <b>1999</b> , 25, 201-22	1.3	563
156	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. <i>Nature Genetics</i> , <b>2017</b> , 49, 27-35	36.3	530
155	microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. <i>Genome Biology</i> , <b>2007</b> , 8, R27	18.3	420
154	The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. <i>Biological Psychiatry</i> , <b>2001</b> , 50, 884-97	7.9	414
153	Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. <i>Biological Psychiatry</i> , <b>2015</b> , 77, 147-57	7.9	384
152	Predictors of noncompliance in patients with schizophrenia. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63, 1121-26	4.86	373
151	An Individualized Risk Calculator for Research in Prodromal Psychosis. <i>American Journal of Psychiatry</i> , <b>2016</b> , 173, 980-988	11.9	332
150	Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. <i>Schizophrenia Bulletin</i> , <b>2009</b> , 35, 894-908	1.3	327
149	North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. <i>Schizophrenia Bulletin</i> , <b>2007</b> , 33, 665-72	1.3	231
148	Association of Thalamic Dysconnectivity and Conversion to Psychosis in Youth and Young Adults at Elevated Clinical Risk. <i>JAMA Psychiatry</i> , <b>2015</b> , 72, 882-91	14.5	199
147	North American Prodrome Longitudinal Study (NAPLS 2): overview and recruitment. <i>Schizophrenia Research</i> , <b>2012</b> , 142, 77-82	3.6	188
146	At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. <i>World Psychiatry</i> , <b>2015</b> , 14, 322-32	14.4	172

145	Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 106-13	4.6	163
144	Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. <i>Biological Psychiatry</i> , <b>2003</b> , 54, 453-64	7.9	161
143	Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study. <i>JAMA Psychiatry</i> , <b>2016</b> , 73, 1239-1248	14.5	158
142	Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. <i>Biological Psychiatry</i> , <b>2013</b> , 74, 410-7	7.9	157
141	Emotion perception and social skill over the course of psychosis: a comparison of individuals "at-risk" for psychosis and individuals with early and chronic schizophrenia spectrum illness. <i>Cognitive Neuropsychiatry</i> , <b>2007</b> , 12, 198-212	2	150
140	Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 419-28	1.3	148
139	Facial affect recognition in individuals at clinical high risk for psychosis. <i>British Journal of Psychiatry</i> , <b>2008</b> , 192, 67-8	5.4	145
138	The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis. <i>Schizophrenia Bulletin</i> , <b>2016</b> , 42, 732-43	1.3	144
137	Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. <i>Schizophrenia Research</i> , <b>2000</b> , 44, 1-10	3.6	139
136	Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. <i>Schizophrenia Research</i> , <b>2006</b> , 83, 53-63	3.6	120
135	Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. <i>British Journal of Psychiatry</i> , <b>2004</b> , 185, 18-24	5.4	120
134	The relationship of neurocognition and negative symptoms to social and role functioning over time in individuals at clinical high risk in the first phase of the North American Prodrome Longitudinal Study. <i>Schizophrenia Bulletin</i> , <b>2014</b> , 40, 1452-61	1.3	117
133	Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. <i>Schizophrenia Bulletin</i> , <b>2003</b> , 29, 33-43	1.3	91
132	Penny-wise and pound-foolish: the impact of measurement error on sample size requirements in clinical trials. <i>Biological Psychiatry</i> , <b>2000</b> , 47, 762-6	7.9	90
131	Nuclear and cytoplasmic localization of neural stem cell microRNAs. <i>Rna</i> , <b>2011</b> , 17, 675-86	5.8	89
130	Multisite reliability of MR-based functional connectivity. <i>NeuroImage</i> , <b>2017</b> , 146, 959-970	7.9	83
129	Cerebello-thalamo-cortical hyperconnectivity as a state-independent functional neural signature for psychosis prediction and characterization. <i>Nature Communications</i> , <b>2018</b> , 9, 3836	17.4	83
128	Early traumatic experiences in those at clinical high risk for psychosis. <i>Microbial Biotechnology</i> , <b>2013</b> , 7, 300-5	3.3	81

127	Expanding the Central dogma: the regulatory role of nonprotein coding genes and implications for the genetic liability to schizophrenia. <i>Molecular Psychiatry</i> , <b>2005</b> , 10, 69-78	15.1	76
126	Comorbid diagnoses for youth at clinical high risk of psychosis. <i>Schizophrenia Research</i> , <b>2017</b> , 190, 90-95	3.6	65
125	The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms. <i>Schizophrenia Bulletin</i> , <b>2017</b> , 43, 57-63	1.3	62
124	Use of Machine Learning to Determine Deviance in Neuroanatomical Maturity Associated With Future Psychosis in Youths at Clinically High Risk. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 960-968	14.5	61
123	Specificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 1066-75	1.3	59
122	Assessment of social judgments and complex mental states in the early phases of psychosis. <i>Schizophrenia Research</i> , <b>2008</b> , 100, 237-41	3.6	59
121	The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. <i>Schizophrenia Research</i> , <b>2009</b> , 115, 50-7	3.6	52
120	Brief evaluation of medication influences and beliefs: development and testing of a brief scale for medication adherence. <i>Journal of Clinical Psychopharmacology</i> , <b>2004</b> , 24, 404-9	1.7	52
119	Stress exposure and sensitivity in the clinical high-risk syndrome: initial findings from the North American Prodrome Longitudinal Study (NAPLS). <i>Schizophrenia Research</i> , <b>2014</b> , 160, 104-9	3.6	50
118	Reliability of an fMRI paradigm for emotional processing in a multisite longitudinal study. <i>Human Brain Mapping</i> , <b>2015</b> , 36, 2558-79	5.9	49
117	Polygenic Risk Score Contribution to Psychosis Prediction in a Target Population of Persons at Clinical High Risk. <i>American Journal of Psychiatry</i> , <b>2020</b> , 177, 155-163	11.9	45
116	Clinical and functional characteristics of youth at clinical high-risk for psychosis who do not transition to psychosis. <i>Psychological Medicine</i> , <b>2019</b> , 49, 1670-1677	6.9	44
115	Anxiety in youth at clinical high risk for psychosis. <i>Microbial Biotechnology</i> , <b>2017</b> , 11, 480-487	3.3	43
114	Early traumatic experiences, perceived discrimination and conversion to psychosis in those at clinical high risk for psychosis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , <b>2016</b> , 51, 497-503	4.5	43
113	Social cognition over time in individuals at clinical high risk for psychosis: Findings from the NAPLS-2 cohort. <i>Schizophrenia Research</i> , <b>2016</b> , 171, 176-81	3.6	41
112	Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry. <i>Molecular Psychiatry</i> , <b>2020</b> , 25, 2455-2467	15.1	41
111	Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort. <i>Microbial Biotechnology</i> , <b>2010</b> , 4, 220-6	3.3	40
110	Lack of Diagnostic Pluripotentiality in Patients at Clinical High Risk for Psychosis: Specificity of Comorbidity Persistence and Search for Pluripotential Subgroups. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, 254-263	1.3	38

109	Theory of Mind, Emotion Recognition and Social Perception in Individuals at Clinical High Risk for Psychosis: findings from the NAPLS-2 cohort. <i>Schizophrenia Research: Cognition</i> , <b>2015</b> , 2, 133-139	2.8	36
108	Severity of thought disorder predicts psychosis in persons at clinical high-risk. <i>Schizophrenia Research</i> , <b>2015</b> , 169, 169-177	3.6	36
107	Mapping genomic loci implicates genes and synaptic biology in schizophrenia.. <i>Nature</i> , <b>2022</b> ,	50.4	35
106	Movement abnormalities predict transitioning to psychosis in individuals at clinical high risk for psychosis. <i>Schizophrenia Research</i> , <b>2014</b> , 159, 263-6	3.6	34
105	Current status specifiers for patients at clinical high risk for psychosis. <i>Schizophrenia Research</i> , <b>2014</b> , 158, 69-75	3.6	34
104	Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort. <i>Schizophrenia Research</i> , <b>2018</b> , 192, 357-363	3.6	32
103	Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis. <i>Brain, Behavior, and Immunity</i> , <b>2019</b> , 76, 268-274	16.6	32
102	Association Between P300 Responses to Auditory Oddball Stimuli and Clinical Outcomes in the Psychosis Risk Syndrome. <i>JAMA Psychiatry</i> , <b>2019</b> , 76, 1187-1197	14.5	30
101	Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011. <i>Schizophrenia Research</i> , <b>2013</b> , 148, 99-104	3.6	30
100	Potential Roles of Redox Dysregulation in the Development of Schizophrenia. <i>Biological Psychiatry</i> , <b>2020</b> , 88, 326-336	7.9	29
99	Theory of mind and social judgments in people at clinical high risk of psychosis. <i>Schizophrenia Research</i> , <b>2013</b> , 150, 498-504	3.6	29
98	Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosis. <i>Schizophrenia Research</i> , <b>2014</b> , 156, 277-80	3.6	29
97	The Global Functioning: Social and Role Scales-Further Validation in a Large Sample of Adolescents and Young Adults at Clinical High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, 763-772	1.3	28
96	Cortical abnormalities in youth at clinical high-risk for psychosis: Findings from the NAPLS2 cohort. <i>NeuroImage: Clinical</i> , <b>2019</b> , 23, 101862	5.3	26
95	Toward Leveraging Human Connectomic Data in Large Consortia: Generalizability of fMRI-Based Brain Graphs Across Sites, Sessions, and Paradigms. <i>Cerebral Cortex</i> , <b>2019</b> , 29, 1263-1279	5.1	25
94	Ventricular enlargement and progressive reduction of cortical gray matter are linked in prodromal youth who develop psychosis. <i>Schizophrenia Research</i> , <b>2017</b> , 189, 169-174	3.6	22
93	Negative symptoms and impaired social functioning predict later psychosis in Latino youth at clinical high risk in the North American prodromal longitudinal studies consortium. <i>Microbial Biotechnology</i> , <b>2015</b> , 9, 467-75	3.3	22
92	Prodromal Symptom Severity Predicts Accelerated Gray Matter Reduction and Third Ventricle Expansion Among Clinically High Risk Youth Developing Psychotic Disorders. <i>Molecular Neuropsychiatry</i> , <b>2015</b> , 1, 13-22	4.9	22

91	Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, 286-296	1.3	21
90	Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium. <i>Schizophrenia Research</i> , <b>2019</b> , 204, 96-103	3.6	21
89	Neuroprotection: A New Strategy in the Treatment of Schizophrenia. <i>CNS Spectrums</i> , <b>2007</b> , 12, 1-16	1.8	20
88	Contribution of Rare Copy Number Variants to Bipolar Disorder Risk Is Limited to Schizoaffective Cases. <i>Biological Psychiatry</i> , <b>2019</b> , 86, 110-119	7.9	20
87	Characterizing Covariant Trajectories of Individuals at Clinical High Risk for Psychosis Across Symptomatic and Functional Domains. <i>American Journal of Psychiatry</i> , <b>2020</b> , 177, 164-171	11.9	19
86	Healthy adolescent performance on the MATRICS Consensus Cognitive Battery (MCCB): Developmental data from two samples of volunteers. <i>Schizophrenia Research</i> , <b>2016</b> , 172, 106-13	3.6	18
85	Patterns of premorbid functioning in individuals at clinical high risk of psychosis. <i>Schizophrenia Research</i> , <b>2015</b> , 169, 209-213	3.6	17
84	Neurocognitive profiles in the prodrome to psychosis in NAPLS-1. <i>Schizophrenia Research</i> , <b>2019</b> , 204, 311-319	3.6	17
83	Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit. <i>Schizophrenia Research</i> , <b>2021</b> , 227, 10-17	3.6	17
82	Functional development in clinical high risk youth: prediction of schizophrenia versus other psychotic disorders. <i>Psychiatry Research</i> , <b>2014</b> , 215, 52-60	9.9	16
81	The content of attenuated psychotic symptoms in those at clinical high risk for psychosis. <i>Psychiatry Research</i> , <b>2014</b> , 219, 506-12	9.9	15
80	Longitudinal study of social support and social conflict as predictors of depression and dysphoria among HIV-positive and HTV-negative gay men. <i>Depression</i> , <b>1994</b> , 2, 189-199		15
79	Functional Capacity Assessed by the Map Task in Individuals at Clinical High-Risk for Psychosis. <i>Schizophrenia Bulletin</i> , <b>2016</b> , 42, 1234-42	1.3	15
78	Latent class cluster analysis of symptom ratings identifies distinct subgroups within the clinical high risk for psychosis syndrome. <i>Schizophrenia Research</i> , <b>2018</b> , 197, 522-530	3.6	14
77	Treatment Precedes Positive Symptoms in North American Adolescent and Young Adult Clinical High Risk Cohort. <i>Journal of Clinical Child and Adolescent Psychology</i> , <b>2018</b> , 47, 69-78	5.4	14
76	Sleep problems and attenuated psychotic symptoms in youth at clinical high-risk for psychosis. <i>Psychiatry Research</i> , <b>2019</b> , 282, 112492	9.9	14
75	Personality disorder in HIV infection. <i>International Review of Psychiatry</i> , <b>1996</b> , 8, 253-258	3.6	14
74	Progressive reconfiguration of resting-state brain networks as psychosis develops: Preliminary results from the North American Prodrome Longitudinal Study (NAPLS) consortium. <i>Schizophrenia Research</i> , <b>2020</b> , 226, 30-37	3.6	14

73	North American Prodrome Longitudinal Study (NAPLS 3): Methods and baseline description. <i>Schizophrenia Research</i> , <b>2020</b> ,	3.6	14
72	Networks of blood proteins in the neuroimmunology of schizophrenia. <i>Translational Psychiatry</i> , <b>2018</b> , 8, 112	8.6	13
71	Evidence that endogenous formaldehyde produces immunogenic and atherogenic adduct epitopes. <i>Scientific Reports</i> , <b>2017</b> , 7, 10787	4.9	13
70	Evaluating and treating the prodromal stage of schizophrenia. <i>Current Psychiatry Reports</i> , <b>2004</b> , 6, 289-95.1	5.1	13
69	Additional layers of gene regulatory complexity from recently discovered microRNA mechanisms. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2010</b> , 42, 1236-42	5.6	12
68	Predictive validity of conversion from the clinical high risk syndrome to frank psychosis. <i>Schizophrenia Research</i> , <b>2020</b> , 216, 184-191	3.6	12
67	Altered Brain Activation During Memory Retrieval Precedes and Predicts Conversion to Psychosis in Individuals at Clinical High Risk. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, 924-933	1.3	12
66	Stressor-Cortisol Concordance Among Individuals at Clinical High-Risk for Psychosis: Novel Findings from the NAPLS Cohort. <i>Psychoneuroendocrinology</i> , <b>2020</b> , 115, 104649	5	11
65	Age-related trajectories of social cognition in youth at clinical high risk for psychosis: An exploratory study. <i>Schizophrenia Research</i> , <b>2018</b> , 201, 130-136	3.6	11
64	Impact of childhood adversity on corticolimbic volumes in youth at clinical high-risk for psychosis. <i>Schizophrenia Research</i> , <b>2019</b> , 213, 48-55	3.6	10
63	Exploration of clinical high-risk dropouts. <i>Schizophrenia Research</i> , <b>2018</b> , 195, 579-580	3.6	10
62	The Violent Content in Attenuated Psychotic Symptoms. <i>Psychiatry Research</i> , <b>2016</b> , 242, 61-66	9.9	10
61	Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis. <i>Psychiatry Research</i> , <b>2014</b> , 218, 39-43	9.9	10
60	Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis. <i>BMC Psychiatry</i> , <b>2015</b> , 15, 276	4.2	10
59	Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis. <i>Psychiatry Research</i> , <b>2015</b> , 230, 878-84	9.9	10
58	The Early Psychosis Screener for Internet (EPSI)-SR: Predicting 12 month psychotic conversion using machine learning. <i>Schizophrenia Research</i> , <b>2019</b> , 208, 390-396	3.6	9
57	Stress perception following childhood adversity: Unique associations with adversity type and sex. <i>Development and Psychopathology</i> , <b>2020</b> , 32, 343-356	4.3	9
56	The Role of microRNA Expression in Cortical Development During Conversion to Psychosis. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 2188-2195	8.7	8

55	The Early Psychosis Screener (EPS): Item development and qualitative validation. <i>Schizophrenia Research</i> , <b>2018</b> , 197, 504-508	3.6	8
54	Clinical trials in schizophrenia with results for the real world. <i>CNS Spectrums</i> , <b>2006</b> , 11, 9-13	1.8	8
53	Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort. <i>Biological Psychiatry</i> , <b>2021</b> , 90, 632-642	7.9	8
52	The relations of age and pubertal development with cortisol and daily stress in youth at clinical risk for psychosis. <i>Schizophrenia Research</i> , <b>2016</b> , 172, 29-34	3.6	8
51	Traumatic brain injury in individuals at clinical high risk for psychosis. <i>Schizophrenia Research</i> , <b>2016</b> , 174, 77-81	3.6	8
50	Adding a neuroanatomical biomarker to an individualized risk calculator for psychosis: A proof-of-concept study. <i>Schizophrenia Research</i> , <b>2019</b> , 208, 41-43	3.6	8
49	The Early Psychosis Screener (EPS): Quantitative validation against the SIPS using machine learning. <i>Schizophrenia Research</i> , <b>2018</b> , 197, 516-521	3.6	7
48	The role of a family history of psychosis for youth at clinical high risk of psychosis. <i>Microbial Biotechnology</i> , <b>2019</b> , 13, 251-256	3.3	7
47	Enhancing stress reactivity and wellbeing in early schizophrenia: A pilot study of individual coping awareness therapy (I-CAT). <i>Schizophrenia Research</i> , <b>2018</b> , 201, 413-414	3.6	6
46	Tobacco use and psychosis risk in persons at clinical high risk. <i>Microbial Biotechnology</i> , <b>2019</b> , 13, 1173-1183	3.3	6
45	Social decline in the psychosis prodrome: Predictor potential and heterogeneity of outcome. <i>Schizophrenia Research</i> , <b>2021</b> , 227, 44-51	3.6	6
44	Incorporating cortisol into the NAPLS2 individualized risk calculator for prediction of psychosis. <i>Schizophrenia Research</i> , <b>2021</b> , 227, 95-100	3.6	6
43	Stability of mismatch negativity event-related potentials in a multisite study. <i>International Journal of Methods in Psychiatric Research</i> , <b>2020</b> , 29, e1819	4.3	5
42	Relation between cannabis use and subcortical volumes in people at clinical high risk of psychosis. <i>Psychiatry Research - Neuroimaging</i> , <b>2016</b> , 254, 3-9	2.9	5
41	Recommendations and Challenges of the Clinical Services Panel of the PhenX Early Psychosis Working Group. <i>Psychiatric Services</i> , <b>2019</b> , 70, 514-517	3.3	5
40	Duration of the psychosis prodrome. <i>Schizophrenia Research</i> , <b>2020</b> , 216, 443-449	3.6	5
39	Enhancing the Treatment of Patients With Schizophrenia Through Continuous Care. <i>Journal of Clinical Psychiatry</i> , <b>2019</b> , 80,	4.6	5
38	Selection for psychosocial treatment for youth at clinical high risk for psychosis based on the North American Prodrome Longitudinal Study individualized risk calculator. <i>Microbial Biotechnology</i> , <b>2021</b> , 15, 96-103	3.3	5



37	Changes in symptom content from a clinical high-risk state to conversion to psychosis. <i>Microbial Biotechnology</i> , <b>2019</b> , 13, 257-263	3.3	4
36	Depression: An actionable outcome for those at clinical high-risk. <i>Schizophrenia Research</i> , <b>2021</b> , 227, 38-43	3.6	4
35	Perceptual abnormalities in clinical high risk youth and the role of trauma, cannabis use and anxiety. <i>Psychiatry Research</i> , <b>2017</b> , 258, 462-468	9.9	3
34	Reliability of mismatch negativity event-related potentials in a multisite, traveling subjects study. <i>Clinical Neurophysiology</i> , <b>2020</b> , 131, 2899-2909	4.3	3
33	Deficits in auditory predictive coding in individuals with the psychosis risk syndrome: Prediction of conversion to psychosis. <i>Journal of Abnormal Psychology</i> , <b>2020</b> , 129, 599-611	7	3
32	Sleep Disturbance in Individuals at Clinical High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , <b>2021</b> ,	1.3	3
31	Genetic and clinical analyses of psychosis spectrum symptoms in a large multiethnic youth cohort reveal significant link with ADHD. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 80	8.6	3
30	Reproducibility and Visual Inspection of Data. <i>Biological Psychiatry</i> , <b>2016</b> , 80, e33-5	7.9	2
29	Systematic discovery of the grammar of translational inhibition by RNA hairpins. <i>Journal of Theoretical Biology</i> , <b>2006</b> , 241, 205-15	2.3	2
28	Markers for schizophrenia. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 1527; author reply 1528	11.9	2
27	Common Data Elements for National Institute of Mental Health-Funded Translational Early Psychosis Research. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , <b>2020</b> , 5, 10-22	3.4	2
26	Cross-paradigm connectivity: reliability, stability, and utility. <i>Brain Imaging and Behavior</i> , <b>2021</b> , 15, 614-629	2.1	2
25	Concordance and factor structure of subthreshold positive symptoms in youth at clinical high risk for psychosis. <i>Schizophrenia Research</i> , <b>2021</b> , 227, 72-77	3.6	2
24	Abnormally Large Baseline P300 Amplitude Is Associated With Conversion to Psychosis in Clinical High Risk Individuals With a History of Autism: A Pilot Study. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 591127	5	2
23	Enhancing stress reactivity and wellbeing in early schizophrenia: A randomized controlled trial of Integrated Coping Awareness Therapy (I-CAT). <i>Schizophrenia Research</i> , <b>2021</b> , 235, 91-101	3.6	2
22	Depression Predicts Global Functional Outcomes in Individuals at Clinical High Risk for Psychosis. <i>Psychiatric Research and Clinical Practice</i> , <b>2021</b> , 3, 163-171	2.7	1
21	Improving Long-Term Outcomes in Patients With Schizophrenia: What Is the Evidence for Long-Acting Injectable Antipsychotics?. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, e1431	4.6	1
20	Managing Transitions in Care and Adherence to Improve Outcomes in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , <b>2019</b> , 80,	4.6	1

19	Association between residential instability at individual and area levels and future psychosis in adolescents at clinical high risk from the North American Prodrome Longitudinal Study (NAPLS) consortium. <i>Schizophrenia Research</i> , <b>2021</b> , 238, 137-144	3.6	1
18	Life Event Stress and Reduced Cortical Thickness in Youth at Clinical High Risk for Psychosis and Healthy Control Subjects. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , <b>2021</b> , 7, 171-174	3.4	1
17	Discriminatory experiences predict neuroanatomical changes and anxiety among healthy individuals and those at clinical high risk for psychosis. <i>NeuroImage: Clinical</i> , <b>2021</b> , 31, 102757	5.3	1
16	Individualized Prediction of Prodromal Symptom Remission for Youth at Clinical High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , <b>2021</b> ,	1.3	1
15	Bullying in clinical high risk for psychosis participants from the NAPLS-3 cohort.. <i>Social Psychiatry and Psychiatric Epidemiology</i> , <b>2022</b> , 1	4.5	0
14	The associations between area-level residential instability and gray matter volumes from the North American Prodrome Longitudinal Study (NAPLS) consortium.. <i>Schizophrenia Research</i> , <b>2022</b> , 241, 1-9	3.6	0
13	Characterizing sustained social anxiety in individuals at clinical high risk for psychosis: trajectory, risk factors, and functional outcomes.. <i>Psychological Medicine</i> , <b>2022</b> , 1-8	6.9	0
12	Visual cortical plasticity and the risk for psychosis: An interim analysis of the North American Prodrome Longitudinal Study. <i>Schizophrenia Research</i> , <b>2021</b> , 230, 26-37	3.6	0
11	Anxiety in youth at clinical high-risk for psychosis: A two-year follow-up. <i>Schizophrenia Research</i> , <b>2021</b> , 236, 87-88	3.6	0
10	The association between migrant status and transition in an ultra-high risk for psychosis population. <i>Social Psychiatry and Psychiatric Epidemiology</i> , <b>2021</b> , 56, 943-952	4.5	0
9	The use of diary methods to evaluate daily experiences in first-episode psychosis.. <i>Psychiatry Research</i> , <b>2022</b> , 312, 114548	9.9	0
8	Family history of psychosis in youth at clinical high risk: A replication study.. <i>Psychiatry Research</i> , <b>2022</b> , 311, 114480	9.9	0
7	miRNA and Schizophrenia <b>2008</b> , 267-281		
6	What have we learned from CATIE about the pharmacologic treatment of schizophrenia?. <i>Current Psychosis &amp; Therapeutics Reports</i> , <b>2006</b> , 4, 35-39		
5	Early Identification and Treatment of Schizophrenia. <i>CNS Spectrums</i> , <b>2007</b> , 12, 5-8	1.8	
4	Evaluating and treating the prodromal stage of schizophrenia. <i>Current Psychosis &amp; Therapeutics Reports</i> , <b>2005</b> , 3, 79-85		
3	Basic auditory processing and emotion recognition in individuals at clinical high risk for psychosis. <i>Schizophrenia Research: Cognition</i> , <b>2022</b> , 27, 100225	2.8	
2	Clinician Recognition of First Episode Psychosis. <i>Journal of Adolescent Health</i> , <b>2021</b> , 69, 457-464	5.8	

- 1 A greedy regression algorithm with coarse weights offers novel advantages.. *Scientific Reports*, **2022**, 12, 5440 4.9